Assembly Biosciences, Inc. (ASMB) Q3 2020 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the Assembly Biosciences Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session after the prepared remarks. As a reminder, this conference call is being recorded. I would now like to hand the call over to Lauren Glazer, Senior Vice President of Investor Relations and Corporate Affairs for Assembly. Please go ahead. Thank you, Bridget. Good morning, and thank you for joining us on such short notice. Today's announcement of our strategic collaboration with Beijing is an exciting and significant milestone for assembly. This collaboration provides a strong foundation to accelerate the development in China of our hepatitis B portfolio, which currently consists of three clinical stage core inhibitors, ABI-H0731 and ABI-H2158, which are an ongoing phase two clinical trials, and ABI-H3733, which is in phase one development. The press release and the slides we will refer to during the call are available in the news and events section of our corporate website at www.assemblybio.com. Please note that a replay of today's call and webcast will also be available from our website. In a moment, I will turn the call over to Dr. John McCutcheson, Assembly's Chief Executive Officer and President, who will discuss the important and strategic benefits of our collaboration with Beijing. Then, Tom Russo, Chief Financial Officer, will review the financial terms and economics of this collaboration for Assembly. Finally, John, Tom, and Jason Okazaki, our chief legal and business officer, will be available for the Q&A portion of the call. Before we begin, I want to remind you that we will be making forward-looking statements, such as statements regarding the potential of our collaboration with...